Sirolimus treatment of severe PTEN hamartoma tumor syndrome: Case report and in vitro studies

Pediatric Research

Volumn 75, Issue 4, 2014, Pages 527-534

  Schmid, Gordian L ^a,b   Kässner, Franziska ^a   Uhlig, Holm H ^c   Körner, Antje ^a,b   Kratzsch, Jürgen ^a   Händel, Norman ^a   Zepp, Fred P ^d   Kowalzik, Frank ^d   Laner, Andreas ^e   Starke, Sven ^a   Wilhelm, Franziska K ^a,b   Schuster, Susanne ^a   Viehweger, Adrian ^a   Hirsch, Wolfgang ^a   Kiess, Wieland ^a   Garten, Antje ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e Medical Genetic Center   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ADIPONECTIN; DACTOLISIB; EVEROLIMUS; KU 0063794; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAPAMYCIN; SOMATOMEDIN BINDING PROTEIN 2; TEMSIROLIMUS; UNCLASSIFIED DRUG; WORTMANNIN; WYE 354;

ADIPOCYTE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BLOOD EXAMINATION; CACHEXIA; CASE REPORT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CLINICAL EXAMINATION; CLINICAL FEATURE; COLONOSCOPY; DRUG EFFECT; HAMARTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INFANT; LIPOMATOSIS; LYMPHOID HYPERPLASIA; NUCLEOTIDE SEQUENCE; PHOSPHATASE AND TENSIN HOMOLOG HAMARTOMA TUMOR SYNDROME; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR VOLUME; WHOLE BODY MRI;

CHILD, PRESCHOOL; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; INFANT; INFANT, NEWBORN; PTEN PHOSPHOHYDROLASE; SIROLIMUS;

EID: 84896460285     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2013.246     Document Type: Article

References (27)

1. Eng C. PTEN: one gene, many syndromes. Hum Mutat 2003;22:183-98.
2. Nelen MR, Kremer H, Konings IB, et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet 1999;7:267-73.
3. Tan MH, Mester JL, Ngeow J, Rybicki LA, Orlof MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012;18:400-7.
4. Bubien V, Bonnet F, Brouste V, et al.; French Cowden Disease Network. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet 2013;50:255-63.
5. Marsh DJ, Trahair TN, Martin JL, et al. Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol 2008;5:357-61.
6. Iacobas I, Burrows PE, Adams DM, Sutton VR, Hollier LH, Chintagump-ala MM. Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation. Pediatr Blood Cancer 2011;57:321-3.
7. Heindl M, Händel N, Ngeow J, et al. Autoimmunity, intestinal lymphoid hyperplasia, and deffects in mucosal B-cell homeostasis in patients with PTEN hamartoma tumor syndrome. Gastroenterology 2012;142:1093-1096.e6.
8. Tremblay F, Gagnon A, Veilleux A, Sorisky A, Marette A. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. Endocrinology 2005;146:1328-37.
9. Yu K, Toral-Barza L, Shi C, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 2009;69:6232-40.
10. García-Martínez JM, Moran J, Clarke RG, et al. Ku-0063794 is a specifc inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 2009;421:29-42.
11. Maira SM, Staufer F, Brueggen J, et al. Identifcation and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ter 2008;7:1851-63.
12. Blumenthal GM, Dennis PA. PTEN hamartoma tumor syndromes. Eur J Hum Genet 2008;16:1289-300.
13. Lopiccolo J, Ballas MS, Dennis PA. PTEN hamartomatous tumor syndromes (PHTS): rare syndromes with great relevance to common cancers and targeted drug development. Crit Rev Oncol Hematol 2007;63:203-14.
14. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8.
15. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118:3065-74.
16. Mehrian-Shai R, Chen CD, Shi T, et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci USA 2007;104:5563-8.
17. Huang S, Liu LN, Hosoi H, Dilling MB, Shikata T, Houghton PJ. p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Cancer Res 2001;61:3373-81.
18. Yellen P, Saqcena M, Salloum D, et al. High-dose rapamycin induces apop-tosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle 2011;10:3948-56.
19. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22:159-68.
20. Matsuzaki H, Daitoku H, Hatta M, Tanaka K, Fukamizu A. Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc Natl Acad Sci USA 2003;100:11285-90.
21. Richardson PG, Eng C, Kolesar J, Hideshima T, Anderson KC. Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol 2012;8:623-33.
22. Cho DC, Hutson TE, Samlowski W, et al. Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma afer progression on vascular endothelial growth factor-targeted therapy. Cancer 2012;118:6055-62.
23. Rosset A, Spadola L, Ratib O. OsiriX: an open-source sofware for navigating in multidimensional DICOM images. J Digit Imaging 2004;17:205-16.
24. Wabitsch M, Brenner RE, Melzner I, et al. Characterization of a human preadipocyte cell strain with high capacity for adipose diferentiation. Int J Obes Relat Metab Disord 2001;25:8-15.
25. Vilar E, Perez-Garcia J, Tabernero J. Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ter 2011;10:395-403.
26. Memorial Sloan-Kettering Cancer Center, Novartis. A Phase 1b/2 Study of BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC), 2013. (http://clinicaltrials.gov/ct2/show/NCT01453595).
27. Aeterna Zentaris, Sarah Cannon Research Institute. A Phase III Randomized Study to Assess the Efcacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients with Refractory Advanced Colorectal Cancer, 2013. (http://clinicaltrials.gov/ct2/show/NCT01097018).